Back to search
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Aged
Locally Advanced Head and Neck Squamous Cell Carcinoma
Clinicaltrials.gov:
EU CTIS:
#2024-520386-31-00
Other:
#NANORAY-312
Interested in this trial?
Email or download this trial
Trials at a glance
Status
Enrolling
Condition
Aged
Locally Advanced Head and Neck Squamous Cell Carcinoma
Trial type
Interventional
Trial phase
Phase 3
Investigational
product
product
Cetuximab
JNJ-90301900 (NBTXR3)
Radiation Therapy
Age
60+ years old
Biological sex
All
Placebo?
No
Trial start date
January 4, 2022
Trial end date
December 31, 2027
CT.gov ID
#NCT04892173
Share the trial ID with your doctor to see if trial participation is right for you. Participation depends on an independent medical assessment.
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
This is a global, open-label, randomized, 2-arm, Investigator's choice Phase 3 (Pivotal
Stage) study to investigate the efficacy and safety of JNJ-90301900 (NBTXR3) / radiation
therapy (RT)±cetuximab versus RT±cetuximab in treatment-naïve, platinum-ineligible,
elderly participants with locally advanced head and neck squamous cell carcinoma
(LA-HNSCC).
Primary outcome measures
- Progression-free Survival (PFS)
Secondary outcome measures
- Overall Survival (OS)
- Local-regional control
- Distant control
- Objective Response Rate (ORR)
- Duration of Overall Response
- Quality of Life over time - QLQ H&N35
- Quality of Life over time - EQ 5D 5L
- Safety across duration of study - AEs
Access detailed information on the trial:
Clinical trials information
© Johnson & Johnson and its affiliates 2025
